B of A Securities Initiates Coverage On Zevia with Neutral Rating, Announces Price Target of $14
B of A Securities analyst Bryan Spillane initiates coverage on Zevia (NYSE:ZVIA) with a Neutral rating and announces Price Target of $14.
Stephens & Co. Initiates Coverage On Zevia with Overweight Rating, Announces Price Target of $19
Stephens & Co. analyst Ben Bienvenu initiates coverage on Zevia (NYSE:ZVIA) with a Overweight rating and announces Price Target of $19.
Wells Fargo Initiates Coverage On Zevia with Overweight Rating, Announces Price Target of $16
Wells Fargo analyst Chris Carey initiates coverage on Zevia (NYSE:ZVIA) with a Overweight rating and announces Price Target of $16.
BMO Capital Initiates Coverage On Zevia with Outperform Rating, Announces Price Target of $24
BMO Capital analyst Andrew Strelzik initiates coverage on Zevia (NYSE:ZVIA) with a Outperform rating and announces Price Target of $24.
Goldman Sachs Initiates Coverage On Zevia with Buy Rating, Announces Price Target of $28
Goldman Sachs analyst Bonnie Herzog initiates coverage on Zevia (NYSE:ZVIA) with a Buy rating and announces Price Target of $28.
Morgan Stanley Initiates Coverage On Zevia with Equal-Weight Rating, Announces Price Target of $14.5
Morgan Stanley analyst Dara Mohsenian initiates coverage on Zevia (NYSE:ZVIA) with a Equal-Weight rating and announces Price Target of $14.5.
Zevia Q2 EPS $(0.30), Sales $34.35M
Zevia (NYSE:ZVIA) reported quarterly losses of $(0.30) per share. The company reported $34.35 million in sales this quarter.
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell
• Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
A Look At Upcoming IPOs For The Week
With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.